Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ATM

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Feb 21, 2024 4:38pm

105 Views

Post# 35891812

RE:RE:RE:ATM

ONC had $40 million cash (CDN) as of September 30, 2024.

They certainly have less now. Perhaps $25 million.

Any CEO without a marketable product or revenue would certainly get nervous having less than one year cash on hand.

MC has no other option at this time but to drain the ATM over and over again, day after day.

BTW, a day with 1 million shares traded will be significantly less than even $300,000 extra in the bank for ONC. Most of the trading is "wash trades" back and forth between friendly accounts to create an illusion of market action.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario